ExploRNA Therapeutics
mRNA technology · mRNA therapeutics & vaccines
Overview
University-of-Warsaw spinout improving mRNA stability and translation via novel cap and nucleoside chemistry — Poland's bet on the mRNA wave.
What they do
ExploRNA Therapeutics is a Polish biotech spun out of the University of Warsaw, building on decades of academic research into mRNA cap chemistry. The company develops next-generation cap analogs and modified-nucleoside chemistry designed to improve the stability and translational efficiency of mRNA, aiming to make mRNA vaccines and therapeutics more potent and durable. At its core is a proprietary library reportedly exceeding 150 cap analogs.
Lead program & status
ExploRNA is a platform-stage company rather than a clinical developer; its lead asset is its cap-analog and mRNA-optimization technology. In 2022 it became the first Polish biotech to receive funding from the Bill & Melinda Gates Foundation (reportedly around USD 0.8 million for a 14-month project). In September 2024 it announced a strategic partnership with US-based Primrose Bio to jointly develop and commercialize mRNA medicines. It has also secured Polish and EU public grants.
Why it matters
ExploRNA represents Poland's bet on the post-COVID mRNA wave, translating world-class Warsaw cap chemistry into licensable technology that could improve mRNA medicines globally.
FAQ
- What is ExploRNA's core technology?
- Proprietary next-generation mRNA cap analogs and modified-nucleoside chemistry that improve mRNA stability and protein translation efficiency, drawing on University of Warsaw research.
- Has ExploRNA received notable funding?
- Yes. In 2022 it became reportedly the first Polish biotech funded by the Bill & Melinda Gates Foundation, alongside Polish and EU grants.
- Does ExploRNA have its own clinical products?
- It is primarily a platform and technology company; it partners with others, such as Primrose Bio (2024), to develop mRNA medicines rather than running its own clinical trials.
Technology
ExploRNA Therapeutics works in mRNA Therapeutics — Turning your own cells into the drug factory.
Read the mRNA Therapeutics brief →Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.